Human trial
The efficacy and safety of thymosin α1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial.
1106 randomized sepsis patients, 22 Chinese centers
Reported findings. No overall mortality advantage
Nonresponse. Corrected 28-day HR0.97 (CI0.76-1.24), P0.82; 90-day HR0.95 (CI0.77-1.17), P0.61. No clear mortality benefit in studied sepsis population.
Harms. No significant safety difference; linked erratum needs reconciliation
Limits. Correction recovered survival data for9 participants and changed lymphocyte data for35/1106 and data-sharing statement. Cached abstracts may retain outdated estimates; use linked correction.
Preparation: Thymosin alpha-1 trial preparation Route: subcutaneous
Read original source ↗Editorial review 2026-10-09. Clinician review pending.